StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$3.20+0.25 (+8.47%)

Close on Nov 18, 2026Market cap $291.16MP/E –Yield –

SAB Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

SAB Biotherapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.32M, down 40.9% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $60.88M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$1.32M-40.9%
FY2023Dec 31, 2023$2.24M-90.6%
FY2022Dec 31, 2022$23.90M-60.7%
FY2021Dec 31, 2021$60.88M+10.2%
FY2020Dec 31, 2020$55.24M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$114.70K-62.4%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$263.14K+207.7%
Q1 FY2024Mar 31, 2024$944.58K+62.5%
Q4 FY2023Dec 31, 2023$305.01K-85.9%
Q3 FY2023Sep 30, 2023$1.27M-64.7%
Q2 FY2023Jun 30, 2023$85.52K-98.7%
Q1 FY2023Mar 31, 2023$581.10K-95.1%
Q4 FY2022Dec 31, 2022$2.16M-80.5%
Q3 FY2022Sep 30, 2022$3.59M-75.5%
Q2 FY2022Jun 30, 2022$6.35M-65.1%
Q1 FY2022Mar 31, 2022$11.80M-30.3%
Q4 FY2021Dec 31, 2021$11.06M–
Q3 FY2021Sep 30, 2021$14.68M–
Q2 FY2021Jun 30, 2021$18.21M–
Q1 FY2021Mar 31, 2021$16.93M–

More SAB Biotherapeutics figures

See a number that looks wrong?